Doxapram versus methylxanthine for apnea in preterm infants

Area of Science:

• Neonatal Medicine
• Pharmacology
• Respiratory Medicine

Background:

• Recurrent apnea is prevalent in preterm infants, potentially causing hypoxemia and bradycardia requiring resuscitation.
• Doxapram and methylxanthine drugs are used to stimulate breathing and prevent apnea in neonates.

Purpose of the Study:

• To compare the efficacy of doxapram versus theophylline in reducing apnea and mechanical ventilation use in preterm infants.
• To assess the safety profile of doxapram compared to theophylline for apnea treatment in neonates.

Main Methods:

• Systematic review and meta-analysis of randomized or quasi-random trials comparing doxapram with methylxanthines for apnea treatment.
• Trials excluded infants with specific causes of apnea.
• Methodological quality assessed, data extracted and synthesized using relative risk and risk difference.

Main Results:

• No apparent difference in apnea incidence within 48 hours between intravenous doxapram and methylxanthine treatment.
• No infants required mechanical ventilation in either treatment group.
• No adverse effects were reported in the included trials.

Conclusions:

• Intravenous doxapram and methylxanthine show similar short-term effectiveness for apnea of prematurity.
• Small trial sizes limit the ability to exclude important differences in efficacy or less common side effects.
• Further large-scale studies are needed to clarify optimal use, identify responsive infants, and assess long-term outcomes and side effects.